Canada's Competition Bureau not challenging GSK, Novartis deal in light of US FTC settlement
MLex Summary: Canada's Competition Bureau has said that it does not currently intend to challenge a major three-part transaction between GlaxoSmithKline and Novartis that pertains to their consumer healthcare, vaccine and...To view the full article, register now.
Already a subscriber? Click here to view full article